Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

Fig. 1

Treatment protocol. PBMCs were separated to prepare RN-T as stimulator cells. One week later, PBMCs were again separated similarly, and re-suspended in culture medium supplemented with heat-inactivated autologous plasma, IL-2 and OK-432. RN-T cells were added to the same flask or culture bag on day 0 and day 7. On days 21–22, the cultured cells were harvested and administered to the patients immediately. Expanded NK cells were intravenously injected for 60 min on days 0, 7, 14 in a dose-escalating manner (dose 0.5 × 109, 1 × 109, 2 × 109 cells/injection, three patients/one cohort). We investigated the dose-limiting toxicity (DLT) occurring over a 28-day period after the last administration of cultured cells. Blood samplings for immune monitoring were done just before the 1st and 3rd administration and 4 weeks after the 3rd administration. PBMCs peripheral blood mononuclear cells, RN-T cells RetroNectin®-induced T cells

Back to article page